Description of Research Expertise:
I am a hematologist-oncologist with a specific research and clinical interest in plasma cell disorders and related dysproteinemias: multiple myeloma, immunoglobulin light chain (AL) amyloidosis, and Waldenstrom’s macroglobulinemia.
I also lead the multi-disciplinary Penn Amyloidosis Program. This is a cross-disciplinary program involving clinicians with expertise in amyloidosis from cardiology, nephrology, pathology and other disciplines.
I am involved in clinical, translational and epidemiologic research throughout the spectrum of plasma cell disorders. My primary research focus is on the myeloma precursor states: monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). I have previously established that both multiple myeloma (Weiss Blood 2009) and AL amyloidosis (Weiss J Clin Oncol 2014) have precursor states that are detectable for many years prior to diagnosis. I have also validated biomarkers for ultra-high risk SMM (Waxman Leukemia 2014) that have contributed to changing the diagnostic criteria for multiple myeloma requiring treatment (Rajkumar Lancet Oncol 2014).
I am currently performing trials to develop and test novel biomarkers for progression in the myeloma precursor states (MGUS and SMM). I am also participating in trials of early intervention in high risk SMM.
I am also conducting trials of novel agents for AL amyloidosis and relapsed and refractory multiple myeloma.
Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Blade J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Segab M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T: Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial Lancet 387 (10027): 1551-60,2016.
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritits E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jaganath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Laheurta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BGM: International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma Lancet Oncol 15 (12): e538-48,2014.
Weiss BM, Hebreo J, Cordaro DV, Roschewski MJ, Baker TP, Abbott KC: Increased Serum Free Light Chains Precede the Presentation of Immunoglobulin Light Chain Amyloidosis J Clin Oncol 32 (25): 2699-704,2014.
Waxman AJ, Mick R, Garfall AL, Cohen A, Vogl DT, Stadtmauer EA: Classifying ultra-high risk smoldering myeloma Leukemia 29 (3): 751-3,2015.
Multiethnic myeloma Blood 121 (16): 3062-4,2013.
Fermand JP, Bridoux F, Kyle RA, Kastritis E, Weiss BM, Cook MA, Drayson MT, Dispenzieri A: How I treat monoclonal gammopathy of renal significance (MGRS) Blood 122 (22): 3583-90,2013.
Minter AR, Simpson H, Weiss BM: Bone Disease From Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: Pathogenesis, Interventions, and Future Opportunities. Seminars in Hematology 48 (1): 55-65,2011.
Weiss BM, Minter A, Abadie J, Howard R, Ascencao J, Schechter GP, Kuehl M: Patterns of Monoclonal Immunoglobulins and Serum Free Light Chains Are Significantly Different in African-American Compared to Caucasian MGUS Patients. American Journal of Hematology 86 (6): 475-8,2011.
Waxman AJ, Mink PJ, Devesa SS, Anderson WF, Weiss BM, Kristinsson SY, McGlynn KA: Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 116 (25): 5501-5506,2010.
Weiss BM, Abadie J, Verma P, Howard RS: A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113 (22): 5418-5422,2009.